DINAMIQS opens new lab in Zurich

DINAMIQS inaugurated its new state-of-the-art R&D and QC laboratories in Zurich’s Bio-Technopark
The new laboratory capacities house leading technologies in the field of viral vector process development and manufacturing, positioning DINAMIQS at the forefront in this critical field
With this expansion, Siegfried is on track to strengthen its position in the fast-growing cell and gene therapy market

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), reached another milestone on its path to strengthen its offering in the biologics space, particularly in the fast-growing cell and gene therapy market. DINAMIQS, which became part of the Siegfried group in May 2023, inaugurated its cutting-edge laboratories in Zurich’s Bio-Technopark, Switzerland.

The new facility houses expanded process development capabilities, including an upstream ball room for different production scales, extended downstream capacities, as well as analytical capabilities, e.g., next-generation sequencing, mass-photometry and a proprietary bioinformatics platform. Adjacent to the R&D labs is an entirely new QC lab with similar technologies under GMP conditions – facilitating the scale up for clinical trials and commercial.

The fully equipped lab features high-end pilot-scale equipment, enabling DINAMIQS to provide clinical viral vector development, analytical and manufacturing services to meet the growing needs of the gene and cell therapy market. It is an integral part of DINAMIQS’ 2,500m² cGMP manufacturing facility for viral vectors, which is currently under construction and set to be operational by the end of 2025. This facility will host up to 1,000L production capacity for the production of viral vectors for R&D, clinical trials, and commercial use under one roof.

Marcel Imwinkelried, Chief Executive Officer Siegfried: “Aligned with Siegfried’s strategy EVOLVE⁺ , the new lab facility marks a key milestone in DINAMIQS’ journey to becoming the leading CDMO in the cell and gene therapy space. The team is making significant strides toward bringing DINAMIQS’ capabilities to commercial scale.”

Martin Kessler, Chief Executive Officer DINAMIQS: “We know about the importance of leading process development and analytics for the success of viral vector projects. This is why we have expanded our Swiss labs significantly. From the optimization of genomes to GMP scale-up our clients now get everything out of one hand.”